Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
BOSTON - Ginkgo Bioworks (NYSE:DNA) announced Friday it has extended its multi-year strategic partnership with Bayer to advance research and development of biological products for agriculture, building on their collaboration that began in 2017. The announcement comes just a week before Ginkgo’s scheduled earnings release on November 7, with the stock showing strong performance of over 57% return in the past year despite recent volatility, according to InvestingPro data.
The extended partnership will continue to focus on developing innovative microbial nitrogen fixation technologies. Under the agreement, Bayer maintains commercialization rights for any resulting biological products that could complement synthetic fertilizers.
Bayer remains a significant partner for Ginkgo’s agricultural biologicals platform, which includes the company’s Research & Development site in West Sacramento. The platform supports collaborations in biological crop protection, nitrogen fixation, and carbon sequestration.
"The future will bring increasingly severe challenges for farmers, and we will best meet these challenges together with leading innovators from around the world through the open innovation ecosystem," said Dr. Mike Graham, Head of R&D at Bayer’s Crop Science Division.
Ginkgo Bioworks will continue working independently with various partners to discover and optimize biological products for agriculture across different crops and geographies.
"Ginkgo is committed to the power of advanced biological tools to deliver innovative products for growers at the forefront of food production and food security worldwide," said Michael Miille, General Manager of Ginkgo’s Agriculture Business Unit.
The announcement comes as agricultural companies increasingly explore biological alternatives and complements to traditional chemical-based solutions. Financial terms of the partnership extension were not disclosed in the company’s press release statement.While Ginkgo reported revenue growth of 25.21% in the last twelve months, reaching $230.81 million, the company continues to face profitability challenges with negative free cash flow of $274.17 million. For comprehensive analysis of Ginkgo Bioworks and 1,400+ other US equities, InvestingPro offers detailed Research Reports that transform complex financial data into actionable intelligence for smarter investing decisions.
In other recent news, Ginkgo Bioworks Holdings reported its Q2 2025 earnings, which showed a significant miss on both earnings per share (EPS) and revenue expectations. The actual EPS was -1.1, falling short of the forecasted -0.1, while revenue came in at 49.6 million, below the anticipated 86.73 million. These results have drawn considerable attention from investors. In another development, the United States District Court for the Northern District of California granted preliminary approval for a settlement regarding multiple stockholder derivative actions against Ginkgo Bioworks. This settlement, initially reached on May 27, 2025, involves lawsuits filed on behalf of the company against certain individuals. The court’s preliminary order requires Ginkgo Bioworks to notify its stockholders about the settlement and has scheduled a final hearing for December 18, 2025. These recent developments are crucial for stakeholders to consider.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.